InsiderTrades.com logo
2025 AI Stock Picks: 2 Hidden Gems Under $10/Share
From Darwin   |   Ad
The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.
👉[Click here to get your FREE report delivered instantly!]
Laura E. Niklason net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Laura Niklason Biography and Net Worth

CEO of Humacyte
Dr. Niklason is the founder of Humacyte and has served as President and Chief Executive Officer since November 2020 and as a member of the Humacyte Board since 2004. Dr. Niklason holds a Ph.D. in Biophysics from the University of Chicago and an M.D. from the University of Michigan. Dr. Niklason has been a member of Humacyte’s Board since the Company’s founding.

What is Laura E. Niklason's net worth?

The estimated net worth of Laura E. Niklason is at least $7.63 million as of November 20th, 2024. Dr. Niklason owns 1,730,884 shares of Humacyte stock worth more than $7,633,198 as of November 20th. This net worth evaluation does not reflect any other investments that Dr. Niklason may own. Additionally, Dr. Niklason receives an annual salary of $899,250.00 as CEO at Humacyte. Learn More about Laura E. Niklason's net worth.

How old is Laura E. Niklason?

Dr. Niklason is currently 61 years old. There are 5 older executives and no younger executives at Humacyte. Learn More on Laura E. Niklason's age.

What is Laura E. Niklason's salary?

As the CEO of Humacyte, Inc., Dr. Niklason earns $899,250.00 per year. Learn More on Laura E. Niklason's salary.

How do I contact Laura E. Niklason?

The corporate mailing address for Dr. Niklason and other Humacyte executives is 1177 AVENUE OF THE AMERICAS 5TH FLOOR, NEW YORK NY, 10036. Humacyte can also be reached via phone at 919-313-9633 and via email at [email protected]. Learn More on Laura E. Niklason's contact information.

Has Laura E. Niklason been buying or selling shares of Humacyte?

Over the course of the past ninety days, Laura E. Niklason has sold $4,751,627.28 in shares of Humacyte stock. Most recently, Laura E. Niklason sold 261,369 shares of the business's stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a transaction totalling $1,150,023.60. Following the completion of the sale, the chief executive officer now directly owns 1,730,884 shares of the company's stock, valued at $7,615,889.60. Learn More on Laura E. Niklason's trading history.

Who are Humacyte's active insiders?

Humacyte's insider roster includes Michael Constantino (Director), Brady Dougan (Director), and Laura Niklason (CEO). Learn More on Humacyte's active insiders.

Are insiders buying or selling shares of Humacyte?

During the last twelve months, Humacyte insiders bought shares 3 times. They purchased a total of 54,412 shares worth more than $369,107.20. During the last twelve months, insiders at the sold shares 13 times. They sold a total of 4,212,973 shares worth more than $25,940,916.90. The most recent insider tranaction occured on November, 20th when CEO Laura E Niklason sold 261,369 shares worth more than $1,150,023.60. Insiders at Humacyte own 11.2% of the company. Learn More about insider trades at Humacyte.

Information on this page was last updated on 11/20/2024.

Laura E. Niklason Insider Trading History at Humacyte

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/20/2024Sell261,369$4.40$1,150,023.601,730,884View SEC Filing Icon  
11/18/2024Sell811,172$4.44$3,601,603.682,419,712View SEC Filing Icon  
9/9/2024Sell157,704$5.42$854,755.683,519,558View SEC Filing Icon  
8/28/2024Sell277,090$6.47$1,792,772.304,029,374View SEC Filing Icon  
6/11/2024Sell358,630$7.08$2,539,100.404,830,658View SEC Filing Icon  
6/3/2024Buy2,050$7.37$15,108.50238,470View SEC Filing Icon  
5/31/2024Sell809,786$7.91$6,405,407.265,381,354View SEC Filing Icon  
9/14/2023Sell2,000,000$2.78$5,560,000.006,191,140View SEC Filing Icon  
8/21/2023Sell602,443$3.39$2,042,281.778,191,140View SEC Filing Icon  
8/17/2023Sell570,174$3.68$2,098,240.329,420,562View SEC Filing Icon  
6/15/2023Sell500,000$3.12$1,560,000.009,990,736View SEC Filing Icon  
6/13/2023Sell4,875,000$2.60$12,675,000.0010,490,736View SEC Filing Icon  
5/25/2023Sell2,625,000$2.75$7,218,750.0015,365,736View SEC Filing Icon  
12/15/2022Sell93,426$2.63$245,710.3818,230,274View SEC Filing Icon  
12/13/2022Sell330,000$2.84$937,200.0018,600,004View SEC Filing Icon  
9/15/2022Buy2,000$4.14$8,280.001,160,240View SEC Filing Icon  
5/23/2022Buy10,000$4.83$48,300.001,158,240View SEC Filing Icon  
12/15/2021Sell125,000$8.88$1,110,000.00View SEC Filing Icon  
See Full Table

Laura E. Niklason Buying and Selling Activity at Humacyte

This chart shows Laura E Niklason's buying and selling at Humacyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Humacyte Company Overview

Humacyte logo
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $4.41
Low: $4.29
High: $4.57

50 Day Range

MA: $5.38
Low: $4.42
High: $6.12

2 Week Range

Now: $4.41
Low: $2.43
High: $9.97

Volume

2,094,875 shs

Average Volume

2,412,612 shs

Market Capitalization

$555.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47
2025 AI Stock Picks: 2 Hidden Gems Under $10/Share
From Darwin   |   Ad
The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.
👉[Click here to get your FREE report delivered instantly!]